In response to a significant decrease in early-stage research spending, Evotec, a leading German company focusing on drug discovery and contract development and manufacturing (CDMO), is undertaking substantial strategic changes. Under the new leadership of CEO Christian Wojczewski, Evotec has
Pfizer Inc. has unveiled a significant advancement in their ongoing Phase 3 MONeT trial, specifically through a substudy aiming to evaluate the efficacy and safety of its RSV vaccine, ABRYSVO, in immunocompromised adults. Historically, this vulnerable population has faced severe complications from
Grail, a leading player in the cancer detection industry, is making a significant cut to its workforce, laying off approximately 350 employees, which represents about 25% of its total workforce. This substantial reduction is part of a major restructuring effort aimed at refocusing the company’s
The U.S. Food and Drug Administration (FDA) has ushered in a new era in cancer treatment with the approval of Tecelra (afamitresgene autoleucel), an innovative therapy aimed at combating synovial sarcoma. This rare and aggressive form of cancer predominantly impacts young adults and has
The biotech landscape is abuzz with the launch of Red Queen Therapeutics, a startup that aims to revolutionize antiviral treatments. Backed by a $55 million investment from venture firm Apple Tree Partners and additional funding from the Biomedical Advanced Research and Development Authority
The recent collaboration between biotech creation engines Two River and Third Rock Ventures has led to the formation of TRC 2004, which has licensed a bispecific T-cell engager (BiTE) from Genor Biopharma. TRC 2004 has acquired the ex-China rights to the CD20/CD3-targeting BiTE, known as GB261,
